Potential Unconventional Medicines for the Treatment of SARS-CoV-2

Authors
Maurizio Coppola1, Raffaella Mondola2

Affiliations
1 Department of Addiction, ASL CN2, Alba, Italy
2 Department of Mental Health, ASL CN1, Saluzzo, Italy

Key words
antiviral drugs, pharmacology, drug research

To the Editor

SARS-CoV-2 infection was first isolated in Wuhan in the end of December 2019, since then, this β-coronavirus has rapidly spread becoming the most important public health concern worldwide. Numerous research Centers are working hard to realize a sure and effective medicine/vaccine as soon as possible, however the timing for having the availability of a curative/preventive treatments are unpredictable. Considering the severe health and economic consequences related with the SARS-CoV-2 pandemic, physicians are testing different antiretroviral and non-antiretroviral drugs for treating infected patients. Scientific literature review has shown interesting information about the potential antiretroviral action of some compounds not conventionally used for the treatment of virosis. Adem and colleagues in their virtual screening based molecular docking study reported a potential binding affinity exerted by various bioflavonoids at the active site of the MPro, the main protease of the SARS-CoV-2 [1]. Potential inhibition properties were studied using the Molprob Virtual Docker Program and some flavonoids, in particular hesperidin, rutin, and diosmin showed a better affinity for the MPro than nelfinavir [1]. Hesperidin showed the highest binding energy at the active site of the MPro with a MoLDock score of –178.5910 (nelfinavir –174.1260 and a HBond of –21.2402. Additionally, in preclinical studies the rutin reduced the level of interleukin 6, a pro-inflammatory cytokine involved in the “cytokine storm” responsible for some severe infection-related complications [3]. Diosmin highlighted the third strongest binding energy at the active site of the MPro with a MoLDock score of –174.1260 and a HBond of –27.2572. As signaled for the rutin, in preclinical models the diosmin reduced the level of interleukin 6 as well as the number of CD4 and CD8 receptors in T cells [4]. Recently, Caly and colleagues reported a potential antiretroviral activity of the anti-parasitic agent ivermectin against SARS-CoV-2 virus. They demonstrated a reduction of about 5000-fold of viral RNA in ivermectin-treated cells compared to control samples after 48 hours treatment. Ivermectin have showed antiviral effects against HIV, West Nile, Venezuelan equine encephalitis, and pseudorabies in previous preclinical and clinical studies [5]. Hoffmann and colleagues have further shown that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for Spike protein priming [6]. So, inhibition of the androgen-regulated serine protease TMPRSS2 activity could be a probable target for antiretroviral treatments. About that, bromhexine, a well tolerated mucolytic acting as cough suppressant, displayed to be able to inhibit the TMPRSS2 in a mice model study [7]. SARS-CoV-2 infection is causing thousands of victims worldwide by subjecting healthcare workers to an unprecedented effort. Despite the absence of clinical evidences regarding some potential anti-SARS-CoV-2 drugs, preliminary information reported by researchers suggest anyhow further studies in order to evaluate the clinical effects as well as the possibility to synthesize derivatives with stronger antiretroviral properties. Compounds reported in our paper have shown a safe profile for human and a potential anti-SARS-CoV2 activity.

Conflict of Interest

The authors declare that they have no conflict of interest.

References


Bibliography

DOI https://doi.org/10.1055/a-1170-4624
Published online: 19.5.2020
Drug Res 2020; 70: 286
© Georg Thieme Verlag KG Stuttgart · New York
ISSN 2194-9379

Correspondence

Dr. Maurizio Coppola
Department of Addiction, ASL CN2
Corso Coppino 46
12051 Alba
Italy
Tel.: +390173316210, Fax : +39017335067
mauriziocoppola1974@gmail.com

Coppola M, Mondola R. Medicines for SARS-CoV-2... Drug Res 2020; 70: 286